Curas.Te
CURAS.TE is a Danish company focused on healthcare diagnostics, offering products and services related to medical testing and diagnostic solutions.
Business. CURAS.TE is a Danish company focused on healthcare diagnostics, offering products and services related to medical testing and diagnostic solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CURAS.TE is a Danish company focused on healthcare diagnostics, offering products and services related to medical testing and diagnostic solutions.
The company's capital structure is characterized by a debt-to-equity ratio of 1.4, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.37, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. The company's free cash flow is negative at -52,416,000 DKK, reflecting ongoing cash outflows from operations after capital expenditures.
Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity of -2.9678 and a return on assets of -1.0634, both of which are negative and indicate a loss-making position. These figures are well below the typical performance of companies in the Biotechnology & Medical Research industry, where positive returns are expected for sustainable operations.
The company's revenue is entirely derived from its healthcare diagnostics segment, with no geographic diversification disclosed in the available data. This concentration in a single business line and geographic market increases exposure to sector-specific and regional risks, such as regulatory changes or market saturation.
The company's growth trajectory is negative, with a revenue decline of 49,676,000 DKK in the latest reporting period. Analysts have not provided a forward-looking revenue outlook, but the current financial performance suggests continued challenges in achieving profitability or growth. The company's operating income and net income are also negative, at -55,592,000 DKK and -53,230,000 DKK, respectively.
Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt, and a high debt load relative to equity. The risk of dilution is assessed as low, with no significant dilution events reported in the latest financial data. However, the company's negative cash flows and high debt-to-equity ratio suggest potential future financing needs that could lead to share dilution.
Recent events include the publication of the latest financial results, which show continued losses and negative cash flows. Analysts have set a mean price target of 8.00 DKK, with all estimates converging at this level, indicating limited upside potential in the near term. The company's earnings per share (EPS) and EBIT estimates are also negative, reflecting ongoing operational challenges.
- CURAS.TE is a healthcare diagnostics company with a high debt-to-equity ratio and negative cash flows.
- The company's profitability metrics are significantly negative, with a return on equity of -2.9678 and a return on assets of -1.0634.
- The company's revenue is entirely concentrated in one segment and geographic market, increasing exposure to sector-specific and regional risks.
- Analysts have set a mean price target of 8.00 DKK, with no significant upside potential in the near term.
- The company's liquidity position is assessed as medium, with a current ratio of 1.37 and negative net cash after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,18 |
| Revenue | —no estimate | —no estimate | —no estimate |
| Operating income | —no estimate | —no estimate | -64,0M DKK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- CURAS.TE Market data — financials · 2026-05-27
- Curasight A/S Market data — analyst estimates · 2026-05-27